ClinVar Miner

Submissions for variant NM_002454.3(MTRR):c.903+469T>C

gnomAD frequency: 0.00007  dbSNP: rs893229476
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000820217 SCV000960921 pathogenic Methylcobalamin deficiency type cblE 2024-01-17 criteria provided, single submitter clinical testing This sequence change falls in intron 6 of the MTRR gene. It does not directly change the encoded amino acid sequence of the MTRR protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. This variant is present in population databases (no rsID available, gnomAD 0.02%). This variant has been observed in individuals with homocystinuria due to cobalamin E deficiency (PMID: 10484769, 12555939, 15714522). This variant is also known as c.903-904ins140. ClinVar contains an entry for this variant (Variation ID: 662553). Studies have shown that this variant results in insertion of 140 nucleotides and introduces a premature termination codon (PMID: 12555939, 20120036). The resulting mRNA is expected to undergo nonsense-mediated decay. For these reasons, this variant has been classified as Pathogenic.
Mendelics RCV000820217 SCV001136811 pathogenic Methylcobalamin deficiency type cblE 2019-05-28 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV001532026 SCV001747403 pathogenic not provided 2023-10-01 criteria provided, single submitter clinical testing MTRR: PM3:Very Strong, PM2, PP4:Moderate, PS3:Moderate
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000820217 SCV004029422 pathogenic Methylcobalamin deficiency type cblE 2023-07-27 criteria provided, single submitter clinical testing Variant summary: MTRR c.903+469T>C alters a non-conserved nucleotide located at a position not widely known to affect splicing. 4/4 computational tools predict no significant impact on normal splicing at the specific intronic location, however, at-least one publication reports experimental evidence that this variant affects mRNA splicing resulting in a pseudoexon inclusion attributed to the creation of an exonic splicing enhancer (Homolova_2010). The variant allele was found at a frequency of 9.6e-05 in 31400 control chromosomes. c.903+469T>C is the most frequent mutation causing the cblE type of homocystinuria and has been reported in the literature in individuals affected with Homocystinuria-Megaloblastic Anemia, cbl E type (example, Wilson_1999, Zavadakova_2002, Lotz-Havla_2021). These data indicate that the variant is likely to be associated with disease. The following publications have been ascertained in the context of this evaluation (PMID: 20120036, 33980297, 10484769, 15714522, 12555939). Four submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. All submitters classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Baylor Genetics RCV003467497 SCV004196487 pathogenic Neural tube defects, folate-sensitive 2023-09-26 criteria provided, single submitter clinical testing
OMIM RCV000820217 SCV000027648 pathogenic Methylcobalamin deficiency type cblE 2002-10-01 no assertion criteria provided literature only
Natera, Inc. RCV000820217 SCV002077201 pathogenic Methylcobalamin deficiency type cblE 2020-11-17 no assertion criteria provided clinical testing
GeneReviews RCV002537460 SCV003354482 not provided Disorders of Intracellular Cobalamin Metabolism no assertion provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.